The Wegovy 0.75 dose: why it doesn't exist (and what does)

Where the 0.75mg figure comes from, and why it causes confusion

Semaglutide is the active ingredient in both Wegovy and Ozempic, which is one reason the two get blurred. Ozempic's titration includes a 0.5mg step that some people round up or describe loosely, and a small number of non-UK sources use decimal patterns that don't match either product's licensed UK schedule. The result is a figure (0.75mg) that circulates on forums and social media but corresponds to no authorised Wegovy dose in the UK.

The NHS medicines page for semaglutide sets out the Wegovy injection schedule plainly: starting dose 0.25mg, then 0.5mg, 1.0mg, 1.7mg, and 2.4mg. That's the pathway. Ozempic's schedule is separate, its purpose is blood-sugar control in type 2 diabetes, and it is not prescribed for weight loss. Confusing the two carries real clinical risk, not least because self-adjusting doses on a prescription medicine (or sourcing one product expecting another) bypasses the clinical oversight that keeps patients safe.

If you've been asking about how Wegovy dosing works in practice, the short answer is that each step is decided by your prescriber based on how well you're tolerating the current level, not on a fixed calendar alone.

What the evidence says about the titration steps that do exist

The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults with obesity over 68 weeks using semaglutide 2.4mg alongside lifestyle support. Average weight reduction was around 15%, a result that sits behind Wegovy's UK licence for weight management. The titration schedule that produced those outcomes is the one described above: four roughly four-weekly steps up to 2.4mg maintenance.

The lower doses (0.25mg and 0.5mg) are tolerability steps. Their job is to let your system adjust before the therapeutic levels kick in. Many of the gastrointestinal side effects that people notice (nausea, looser stools, indigestion) are most prominent in these early weeks, and the slow climb is specifically designed to reduce them. Moving faster doesn't improve outcomes; it usually means feeling worse and sometimes stopping treatment prematurely.

For patients who want to understand the full range of Wegovy doses and how they're sequenced, the prescriber conversation is the right place to dig into timings, because individual response, not a fixed rule, shapes when a step-up happens.

In January 2026 the MHRA also issued a Drug Safety Update for GLP-1 medicines highlighting acute pancreatitis as an infrequent but potentially serious side effect. Severe stomach pain that spreads to the back, with or without vomiting, needs urgent medical attention, don't wait for your next review.

The 7.2mg dose: what's changed since 2024

Wegovy's story moved on significantly. On 14 April 2026 the MHRA approved a dedicated single-dose 7.2mg pen, one pre-set weekly injection with a built-in covered needle that locks after use. This higher maintenance dose is authorised for adults with a BMI of 30 or above; it is not available for the cardiovascular indication, and it is not for everyone. Trial data put average weight loss at around 20.7% over 72 weeks at 7.2mg, which starts to approach results seen with tirzepatide at its highest licensed dose.

The path to 7.2mg still begins at 0.25mg, and if you want to understand what that upper end of the schedule involves, our page on the 1.75mg Wegovy step explains where it sits in the titration sequence before the maintenance ceiling is reached. There are no shortcuts through the schedule, and a prescriber (not the patient) decides whether the higher ceiling is clinically appropriate. You can read more about how the Wegovy pen doses are structured and what the newer format means in practice.

If you're weighing up how Wegovy compares with tirzepatide overall, our weight-loss treatment overview lays out the licensed options without the noise.

Getting the right dose through a regulated route

Prescription-only medicines like Wegovy are dispensed against a prescription written by a registered prescriber, that's not a bureaucratic detail, it's the mechanism that matches the right dose to the right patient. A prescriber checking your medical history, current medicines, and weight trajectory before every step-up is the system working as it should.

At nume, a GPhC-registered Independent Prescriber reads every consultation, your responses aren't filtered through software first. Our pharmacy (GPhC registration 9012878, verifiable on the GPhC register) dispatches the same working day when orders arrive before midday and a prescriber has approved them, with free tracked next-day delivery via DPD. Plain packaging, nothing printed on the outside. That's the part patients tell us they notice first.

No subscriptions, no auto-renewals. Before any repeat or dose step-up, there's a fresh clinical review. If you're curious whether Wegovy is the right fit for your situation, this page on where Wegovy can be obtained in the UK covers what to look for in a regulated provider. Alternatively, you can check your eligibility through a free consultation with our prescribers.